In order to accelerate innovation, domestic and foreign pharmaceutical companies have set off a wave of cooperation

In recent years, the "marriage" of cooperation between pharmaceutical companies has already become the norm
.
This year, this situation has been very common
.
For example, the cooperation between local pharmaceutical companies and innovative pharmaceutical companies, innovative pharmaceutical companies and multinational pharmaceutical companies, and large and small companies is increasing, and the amount of cooperation involved is also increasing
.
It is reported that in recent days, a number of pharmaceutical companies have announced cooperation in new drug research and development, artificial intelligence and other fields
.
For example, on March 10, Biositu announced that it authorized BeiGene to use the RenMab®/RenLite® fully human antibody mouse platform with independent intellectual property rights to develop fully human monoclonal antibodies, double antibodies and other types of antibodies.
Antibody drugs
.
It is reported that Biocytogen's fully human antibody mouse RenMice platform (RenMab® and RenLite®) was developed by Biocytogen in five years using the self-developed super-segment chromosome engineering technology SUPCE
.
Coincidentally, Insilicon also announced a research and development cooperation with the transformation team of the University of Zurich on the same day
.
It will work with the team's Mechanisms of Inherited Kidney Diseases (MIKADO) group to accelerate the discovery of transformative and innovative treatments for cystinosis for an initial period of one year
.
Under the collaboration agreement, the MIKADO group will use its multi-omics database obtained from preclinical models and cellular models of cystinosis to identify patients with cystinosis through Insilico's AI target discovery platform PandaOmics The cellular and molecular pathways that present life-threatening complications
.
On March 9, Voyager Therapeutics announced that it has entered into a licensing and research and development agreement with Novartis, which gives Novartis the right to acquire development rights to the innovative AAV capsids developed by Voyager's AAV capsid discovery platform, targeting three unpublished AAV capsids.
Central Nervous System (CNS) Targets
.
Novartis also has options to acquire capsids targeting two additional targets
.
On March 8, GenScript Biotech Co.
, Ltd.
announced that based on the cooperation and license agreement signed by its subsidiary Legend Biotech on December 21, 2017 with Janssen Biotech, Inc, a provisional agreement was signed on February 28, 2022.
In the product supply agreement, Legend America will supply Janssen with the recently approved CAR-T cell therapy product Cedarquiorenza/Carvykti (ciltacabtagene autoleucel; cilta-cel) for global clinical and commercial use (except large China)
.
On the whole, since this year, a large number of domestic and foreign companies have announced that they will cooperate with other companies
.
The analysis believes that this is mainly due to the influence of changes in the pharmaceutical industry, pharmaceutical companies have successively adjusted their strategies, in order to speed up the layout of different pipelines, and to accelerate the formation of groups and other reasons
.
In the future, under the background of accelerated reshuffle in the pharmaceutical industry and accelerated innovation and transformation of pharmaceutical companies, in order to achieve complementary advantages, pharmaceutical companies will flexibly mobilize resources from both parties to better promote R&D.
Such cooperation cases are expected to increase
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.